By Professor Sean Emery

Book Chapters

Emery S, 2013, 'Lipid Peroxidation, Antioxidants and Regenerating Rat Liver', in Nigram SK (ed.), Eicosanoids, Lipid Peroxidation and Cancer, Springer Science & Business Media, pp. 195 - 202

Pett SL; Emery S; Cooper DA, 2006, 'Initial treatment of HIV-1 infection. Online access: www.antimicrobe.org', in Singh N; Swindells S; Shafer R (ed.), HIV Clinical Manual, edn. Original, ESun Technologies, LLC, online

Ramacciotti TP; Smith DE; Emery S; Kelleher AD; Cooper DA, 2005, 'Therapeutic vaccination in PHI', in Jenssen H; Jager H (ed.), Primary HIV Infection ? Pathology, Diagnosis, Management, Thieme, Stuttgart, pp. 48 - 63

Journal articles

MacDonald DM; Samorodnitsky S; Wendt CH; Baker JV; Collins G; Kruk M; Lock EF; Paredes R; Poongulali S; Weise DO; Winston A; Wood R; Kunisaki KM; Aagaard B; Jansson PO; Pearson MT; Babiker AG; Arenas-Pinto A; Atako NB; Dennis E; Forcat S; Hudson F; Jackson B; Maas D; Purvis C; Russell C; Emery S; Carey C; Clewett M; Jacoby S; Gordin F; Vjecha M; Sanchez A; Loria GR; Doldan ML; Moricz A; Tillmann K; Müller V; Touloumi G; Gioukari V; Anagnostou O; Herrero P; Lopez P; Avihingsanon A; Rerksirikul P; Loiza E; Mingrone V; Lupo S; Marconi F; Daniel D; Crinejo A; French M; Barba L; Rowling D; Warzywoda E; Bloch M; Agrawal S; Dwyer D; Taylor J; van Petersen L; Mertens L; De Wit S; Kabamba K; Wolff M; Allendes G; Ristola M; Debham O; Jessen H; Jessen A; Wiebecke S; Klinker H; Fätkenheuer G; Lehmann C; Knaevelsrud I; Rittweger M; Stöhr A; Olah K; Schaaf B; Hower M; Harrer T; Harrer E; Skoutelis A; Papastamopoulos V; Metallidis S; Tsachouridou O; Pujari S; Chitalikar A; Kumarasamy N; Beulah F; Shahar E; Kedem E; Turner D; Madero JS; Madrigal C; Filali MKE; Erradey I; Ekong E; Eriobu N; Valencia J; León M, 2023, 'Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-29739-x

Lundgren JD; Babiker AG; Sharma S; Grund B; Phillips AN; Matthews G; Kan VL; Aagaard B; Abo I; Alston B; Arenas-Pinto A; Avihingsanon A; Badal-Faesen S; Brites C; Carey C; Casseb J; Clarke A; Collins S; Corbelli GM; Dao S; Denning ET; Emery S; Eriobu N; Florence E; Furrer H; Fätkenheuer G; Gerstoft J; Gisslén M; Goodall K; Henry K; Horban A; Hoy J; Hudson F; Azwa RISR; Kedem E; Kelleher A; Kityo C; Klingman K; Rosa AL; Leturque N; Lifson AR; Losso M; Lutaakome J; Madero JS; Mallon P; Mansinho K; Filali KME; Molina J-M; Murray DD; Nagalingeswaran K; Nozza S; Ormaasen V; Paredes R; Peireira LC; Pillay S; Polizzotto MN; Raben D; Rieger A; Sanchez A; Schechter M; Sedlacek D; Staub T; Touloumi G; Turner M; Madruga JV; Vjecha M; Wolff M; Wood R; Zilmer K; Lane HC; Neaton JD; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group , 2023, 'Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.', NEJM Evid, 2, http://dx.doi.org/10.1056/evidoa2200302

Burnett DL; Jackson KJL; Langley DB; Aggrawal A; Stella AO; Johansen MD; Balachandran H; Lenthall H; Rouet R; Walker G; Saunders BM; Singh M; Li H; Henry JY; Jackson J; Stewart AG; Witthauer F; Spence MA; Hansbro NG; Jackson C; Schofield P; Milthorpe C; Martinello M; Schulz SR; Roth E; Kelleher A; Emery S; Britton WJ; Rawlinson WD; Karl R; Schäfer S; Winkler TH; Brink R; Bull RA; Hansbro PM; Jäck HM; Turville S; Christ D; Goodnow CC, 2021, 'Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability', Immunity, 54, pp. 2908 - 2921.e6, http://dx.doi.org/10.1016/j.immuni.2021.10.019

Gray J; Prestage G; Jin F; Phanuphak N; Friedman RK; Fairley CK; Kelleher A; Templeton D; Zablotska-Manos IB; Hoy J; McNulty A; Pell C; Grulich A; Bavinton B; Grinsztejn B; Cooper DA; Emery S; Wilson D; Koelsch KK; Triffitt K; Doong N; Baker D; Bloch M; Tee BK; Moore R; Roth N; Orth D; Pinto AN, 2021, 'Characteristics of Agreements to have Condomless Anal Intercourse in the Presence of an Undetectable Viral Load Among HIV Serodiscordant Male Couples in Australia, Brazil and Thailand', AIDS and Behavior, 25, pp. 3944 - 3954, http://dx.doi.org/10.1007/s10461-021-03324-7

Dwyer DE; Lynfield R; Losso MH; Davey RT; Cozzi-Lepri A; Wentworth D; Uyeki TM; Gordin F; Angus B; Qvist T; Emery S; Lundgren J; Neaton JD, 2020, 'Comparison of the outcomes of individuals with medically attended influenza a and b virus infections enrolled in 2 international cohort studies over a 6-year period: 2009-2015', Open Forum Infectious Diseases, 4, http://dx.doi.org/10.1093/ofid/ofx212

Lampe FC; Rodger AJ; Burman W; Grulich A; Friedland G; Sadr WE; Neaton J; Corbelli GM; Emery S; Molina JM; Orkin C; Gatell J; Gerstoft J; Ruxrungtham K; Barbosa De Souza M; Phillips AN, 2019, 'Impact of early antiretroviral treatment on sexual behaviour: A randomised comparison', AIDS, 33, pp. 2337 - 2350, http://dx.doi.org/10.1097/QAD.0000000000002359

Lampe FC; Rodger AJ; Burman W; Grulich A; Friedland G; Sadr WE; Neaton J; Corbelli GM; Emery S; Molina JM; Orkin C; Gatell J; Gerstoft J; Ruxrungtham K; Barbosa de Souza M; Phillips AN; INSIGHT START Study Group , 2019, 'Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison.', AIDS, 33, pp. 2337 - 2350, http://dx.doi.org/10.1097/QAD.0000000000002359

Sereti I; Gulick RM; Krishnan S; Migueles SA; Palfreeman A; Touzeau-Römer V; Belloso WH; Emery S; Law MG; Han A, 2019, 'ART in HIV-Positive Persons with Low Pretreatment Viremia: Results from the START Trial', Journal of Acquired Immune Deficiency Syndromes, 81, pp. 456 - 462, http://dx.doi.org/10.1097/QAI.0000000000002052

Sereti I; Gulick RM; Krishnan S; Migueles SA; Palfreeman A; Touzeau-Römer V; Belloso WH; Emery S; Law MG; INSIGHT START Study Group , 2019, 'ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.', J Acquir Immune Defic Syndr, 81, pp. 456 - 462, http://dx.doi.org/10.1097/QAI.0000000000002052

Revell AD; Wang D; Perez-Elias M-J; Wood R; Tempelman H; Clotet B; Reiss P; van Sighem AI; Alvarez-Uria G; Nelson M; Montaner JSG; Lane HC; Larder BA; Harrigan R; de Wit TR; Hamers R; Sigaloff K; Agan B; Marconi V; Wegner S; Sugiura W; Zazzi M; Kaiser R; Schuelter E; Streinu-Cercel A; Bals M; Alvarez-Uria G; Perez-Elias M-J; de Oliveira T; Gatell J; Lazzari E; Gazzard B; Nelson M; Pozniak A; Mandalia S; Smith C; Ruiz L; Clotet B; Staszewski S; Torti C; Lane HC; Julia A; Metcalf ; Rehm CA; Perez-Elias M-J; Vella S; Dettorre G; Carr A; Norris R; Hesse K; Vlahakis E; Tempelman H; Barth R; Wood R; Morrow C; Cogill D; Hoffmann C; Ene L; Dragovic G; Diaz R; Sucupira C; Sued O; Cesar C; Sierra Madero J; Balakrishnan P; Saravanan S; Emery S; Cooper D; Torti C; Baxter J; Monno L; Gatell J; Clotet B; Picchio G; deBethune M-P; Emery S; Khabo P; Ledwaba L, 2019, 'Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response', JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 81, pp. 207 - 215, http://dx.doi.org/10.1097/QAI.0000000000001989

Singkham N; Avihingsanon A; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Burger DM; Emery S; Punyawudho B, 2019, 'Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients', Pharmacogenomics, 20, pp. 517 - 527, http://dx.doi.org/10.2217/pgs-2018-0196

Boatman JA; Baker JV; Emery S; Furrer H; Mushatt DM; Sedláček D; Lundgren JD; Neaton JD, 2019, 'Risk Factors for Low CD4⁺ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4⁺ Counts > 500 Cells/mm³: Findings from the Strategic Timing of AntiRetroviral Therapy (START) Trial', Journal of Acquired Immune Deficiency Syndromes, 81, pp. 10 - 17, http://dx.doi.org/10.1097/qai.0000000000001967

Bavinton BR; Prestage GP; Jin F; Phanuphak N; Grinsztejn B; Fairley CK; Baker D; Hoy J; Templeton DJ; Tee BK; Kelleher A; Grulich AE; Zablotska-Manos I; Cooper D; Triffitt K; Bloch M; McNulty A; Pell C; Emery S, 2019, 'Strategies used by gay male HIV serodiscordant couples to reduce the risk of HIV transmission from anal intercourse in three countries', Journal of the International AIDS Society, 22, pp. e25277, http://dx.doi.org/10.1002/jia2.25277

Dharan NJ; Neuhaus J; Rockstroh JK; Peters L; Gordin F; Arenas-Pinto A; Emerson C; Marks K; Hidalgo J; Sarmento-Castro R; Stephan C; Kumarasamy N; Emery S; Matthews GV, 2019, 'Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial', Hepatology, 69, pp. 1135 - 1150, http://dx.doi.org/10.1002/hep.30296

Borges Á; Neuhaus J; Sharma S; Neaton JD; Henry K; Anagnostou O; Staub T; Emery S; Lundgren JD, 2019, 'The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis', Journal of Infectious Diseases, 219, pp. 254 - 263, http://dx.doi.org/10.1093/infdis/jiy442

Polizzotto M; Van Bockel D; Law C; Roberts J; Buckland G; Just S; Comben S; Hillman R; Gilson R; Pett S; Poynten M; Law M; Kelleher A; Emery S, 2019, 'Clearance of HPV Anal Premalignant Lesions and Modulation of Systemic Immune Responses to HPV Oncogenes with Low Dose Pomalidomide', Annals of Oncology, 30, pp. xi35 - xi35, http://dx.doi.org/10.1093/annonc/mdz451.005

Brummel-Ziedins KE; Gissel M; Neuhaus J; Borges ÁH; Chadwick DR; Emery S; Neaton JD; Tracy RP; Baker JV, 2018, 'In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus', Research and Practice in Thrombosis and Haemostasis, 2, pp. 708 - 717, http://dx.doi.org/10.1002/rth2.12147

Kent SJ; Hough S; Kelleher AD; Law MG; Hutchinson J; Catalfarmo M; van Bockel D; Lane C; Baker JV; Emery S; Han A, 2018, 'Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial', The Lancet HIV, 5, pp. e553 - e559, http://dx.doi.org/10.1016/S2352-3018(18)30214-5

Vanderven HA; Wragg K; Ana-Sosa-Batiz F; Kristensen AB; Jegaskanda S; Wheatley AK; Wentworth D; Wines BD; Hogarth PM; Rockman S; Kent SJ; INSIGHT FLU005 Pilot Study Writing Group , 2018, 'Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection.', J Infect Dis, 218, pp. 1383 - 1393, http://dx.doi.org/10.1093/infdis/jiy328

Trevillyan JM; Wong G; Puls R; Petoumenos K; Emery S; Mellett NA; Mundra PA; Meikle PJ; Hoy JF, 2018, 'Changes in plasma lipidome following initiation of antiretroviral therapy', PLoS ONE, 13, pp. e0202944, http://dx.doi.org/10.1371/journal.pone.0202944

Bavinton BR; Pinto AN; Phanuphak N; Grinsztejn B; Prestage GP; Zablotska-Manos IB; Jin F; Fairley CK; Moore RD; Roth N; Bloch M; Pell C; McNulty AM; Baker D; Hoy J; Tee BK; Templeton DJ; Cooper DA; Emery S; Kelleher A; Grulich AE; Bas A; Cooper DA; Wilson D; Koelsch KK; Triffitt K; Doong N; Baker D; Bloch M; McNulty A; Pell C; Hoy J; Tee BK; Orth D; Pinto AN, 2018, 'Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study', The Lancet HIV, 5, pp. e438 - e447, http://dx.doi.org/10.1016/S2352-3018(18)30132-2

Simonsen L; Higgs E; Taylor RJ; Wentworth D; Cozzi-Lepri A; Pett S; Dwyer DE; Davey R; Lynfield R; Losso M; Morales K; Glesby MJ; Weckx J; Carey D; Lane C; Lundgren J; Emery S, 2018, 'Using clinical research networks to assess severity of an emerging influenza pandemic', Clinical Infectious Diseases, 67, pp. 341 - 349, http://dx.doi.org/10.1093/cid/ciy088

Forsberg LK; Anyika M; You Z; Emery S; McMullen M; Dobrowsky RT; Blagg BSJ, 2018, 'Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects', EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 143, pp. 1428 - 1435, http://dx.doi.org/10.1016/j.ejmech.2017.10.038

Pett SL; Kunisaki KM; Wentworth D; Griffin TJ; Kalomenidis I; Nahra R; Sanchez RM; Hodgson SW; Ruxrungtham K; Dwyer D; Davey RT; Wendt CH; Lundgren J; Jansson P; Pearson M; Aagaard B; Hudson F; Bennet R; Pacciarini F; Angus B; Paton N; Collaco Moraes Y; Cooper D; Emery S; Courtney-Rogers D; Robson R; Gordin F; Sanchez A; Standridge B; Vjecha M; Moricz A; Delfino M; Belloso W; Losso M; Tillmann K; Touloumi G; Gioukari V; Anagnostou O; La Rosa A; Saenz MJ; Lopez P; Herrero P; Portas B; Kaewon P; Ubolyam S; Brekke K; Campbell M; Denning E; DuChene A; Engen N; George M; Harrison M; Neaton JD; Nelson R; Quan SF; Schultz T; Baxter J; Brown S; Hoover M; Beigel J; Dewar R; Gover E; McConnell R; Metcalf J; Natarajan V; Rehman T; Voell J; Dwyer DE; Kok J; Uyeki T; Munroe D; Paez A; Bertrand M; Temesgen Z; Rizza S; Wolfe C; Carbonneau J; Novak R; Schwarber M; Polenakovik H; Clark L; Patil N; Riska P; Omotosho J; Faber L; Markowitz N; Glesby M; Ham K; Parenti D; Simon G; Coburn P; Freiberg M; Koerbel G; Dharan N; Paez-Quinde M; Gunter J; Beilke M; Lu Z; Gunderson E; Baker J, 2018, 'Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study', Open Forum Infectious Diseases, 5, pp. ofx228, http://dx.doi.org/10.1093/ofid/ofx228

Yao AH; Moore CL; Lim PL; Molina JM; Madero JS; Kerr S; Mallon PWG; Emery S; Cooper DA; Boyd MA, 2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S; Fisher M; Rockstroh J; Stellbrink J; Merlin K; Yeung J; Fsadni B; Marks K; Suzuki K; Rismanto N; Salomon H; Rubio AE; Chibo D; Birch C; Swenson L; Chan D; Berg T; Obermeier M; Schuelter E; Aragon SS; Luebke N; Coughlan S; Dean J; Iwatani Y; Teran GR; Avila S; Sirivichayakul S; Naphassanant M; Ubolyam S; Kaye S; Land S; Walker S; Haubrich R; DeJesus E; Berthon-Jones N; Espinosa N; Courtney-Vega K; Absar N; Haskelberg H; Robson R; Donaldson A; Guelman D; Gambardella L; Valdovinos M; Arnaiz J; Beleta H; Ramos N; Targa M; Späth B; Boesecke C; Engelhardt A; Perry N; Beckthold B; Drummond F; Lefevre E; Corr S; Grant C; Lupo S; Peroni L; Sanchez M; De Paz Sierra M; Viloria G; Parlante A; Bissio E; Luchetti P; Confalonieri V; Warley E; Vieni I; Vilas C; Zarate A; Mayer G; Elliot J; Hagenauer M; Kelley M; Bloch M; Cooper D, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532

Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus Nordwall J; Johnson M; Vjecha MJ; Kelleher AD; Emery S; Han A, 2017, 'Circulating MIR-122 and MIR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals', Scientific Reports, 7, pp. 10934, http://dx.doi.org/10.1038/s41598-017-11405-8

Murray JM; Zaunders J; Emery S; Cooper DA; Hey-Nguyen WJ; Koelsch KK; Kelleher AD, 2017, 'HIV dynamics linked to memory CD4+ T cell homeostasis', PLoS ONE, 12, pp. e0186101, http://dx.doi.org/10.1371/journal.pone.0186101

Madhavi V; Wines BD; Amin J; Emery S; Lopez E; Kelleher A; Center RJ; Mark Hogarth P; Chung AW; Kent SJ; Stratov I, 2017, 'HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV', Journal of Virology, 91, pp. e00700 - e00717, http://dx.doi.org/10.1128/JVI.00700-17

Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Mark Hogarth P; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ, 2017, 'Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption', Journal of Virology, 91, pp. e00603 - e00617, http://dx.doi.org/10.1128/JVI.00603-17

Madhavi V; Kulkarni A; Shete A; Lee WS; McLean MR; Kristensen AB; Ghate M; Wines BD; Hogarth PM; Parsons MS; Kelleher A; Cooper DA; Amin J; Emery S; Thakar M; Kent SJ, 2017, 'Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts', Journal of Acquired Immune Deficiency Syndromes, 75, pp. 345 - 353, http://dx.doi.org/10.1097/qai.0000000000001380

Peterson RL; Vock DM; Powers JH; Emery S; Cruz EF; Hunsberger S; Jain MK; Pett S; Neaton JD, 2017, 'Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization', Clinical Trials, 14, pp. 264 - 276, http://dx.doi.org/10.1177/1740774517697919

Baker JV; Sharma S; Achhra AC; Bernardino JI; Bogner JR; Duprez D; Emery S; Gazzard B; Gordin J; Grandits G; Phillips AN; Schwarze S; Soliman EZ; Spector SA; Tambussi G; Lundgren J, 2017, 'Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial', Journal of the American Heart Association, 6, pp. e004987, http://dx.doi.org/10.1161/JAHA.116.004987

Lifson AR; Grund B; Gardner EM; Kaplan R; Denning E; Engen N; Carey CL; Chen F; Dao S; Florence E; Sanz J; Emery S, 2017, 'Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection', AIDS, 31, pp. 953 - 963, http://dx.doi.org/10.1097/qad.0000000000001417

Boyd MA; Amin J; Mallon PWG; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA, 2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study', The Lancet HIV, 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8

Amara AB; Else LJ; Carey D; Khoo S; Back DJ; Amin J; Emery S; Puls RL, 2017, 'Comparison of dried blood spots versus conventional plasma collection for the characterization of efavirenz pharmacokinetics in a large-scale global clinical trial-the ENCORE1 study', Therapeutic Drug Monitoring, 39, pp. 654 - 658, http://dx.doi.org/10.1097/FTD.0000000000000448

Baker JV; Sharma S; Grund B; Rupert A; Metcalf JA; Schechter M; Munderi P; Aho I; Emery S; Babiker A; Phillips A; Lundgren JD; Neaton JD; Lane HC, 2017, 'Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial', Open Forum Infectious Diseases, 4, pp. ofx262, http://dx.doi.org/10.1093/ofid/ofx262

Lee WS; Kristensen AB; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport M; Emery S; Amin J; Cooper DA; Kan V; Fox J; Grüll H; Parsons MS; Kent SJ; Rasmussen TA, 2017, '13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption', Journal of Virus Eradication, 3, pp. 10 - 10, http://dx.doi.org/10.1016/s2055-6640(20)30718-4

Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE, 2016, 'Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial', The Lancet Respiratory Medicine, 4, pp. 980 - 989, http://dx.doi.org/10.1016/S2213-2600(16)30319-8

Boatman J; Baker J; Emery S; Mushatt D; Furrer H; Sedláček D; Lundgren J; Neaton J, 2016, 'Risk Factors for Low Immune Recovery Among Participants with CD4+ Counts > 500 cells/mm3 who Achieved Viral Suppression in the Immediate Antiretroviral Treatment (ART) Group in Strategic Timing of Antiretroviral Treatment (START) Trial', Open Forum Infectious Diseases, 3, http://dx.doi.org/10.1093/ofid/ofw172.1223

Taychakhoonavudh S; Maneesawangwong N; Bunupuradah T; Kiertiburanakul S; Worrathammasorn T; Hadnorntun P; Avihingsanon A; Chetchotisakd P; Emery S; Ruxrungtham K, 2016, 'COST-UTILITY ANALYSIS OF ATAZANAVIR/RITONAVIR 200/100 MG VERSUS ATAZANAVIR/RITONAVIR 300/100 MG IN THAI ADULTS WITH VIROLOGIC SUPPRESSION', VALUE IN HEALTH, 19, pp. A912 - A912, http://dx.doi.org/10.1016/j.jval.2016.08.148

Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers RL; Reiss P; van Sighem AI; Nelson M; Montaner JSG; Lane HC; Larder BA; Harrigan R; de Wit TR; Sigaloff K; Agan B; Marconi V; Wegner S; Sugiura W; Zazzi M; Kaiser R; Schuelter E; Streinu-Cercel A; Alvarez-Uria G; Gatell J; Lazzari E; Gazzard B; Pozniak A; Mandalia S; Webster D; Smith C; Ruiz L; Clotet B; Staszewski S; Torti C; Lane C; Metcalf J; Perez-Elias MJ; Vella S; Dettorre G; Carr A; Norris R; Hesse K; Vlahakis E; Barth R; Hoffmann C; Ene L; Dragovic G; Diaz R; Sucupira C; Sued O; Cesar C; Madero JS; Emery S; Cooper D; Baxter J; Monno L; Picchio G; deBethune MP; Khabo P; Ledwaba L, 2016, 'An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype', Journal of Antimicrobial Chemotherapy, 71, pp. 2928 - 2937, http://dx.doi.org/10.1093/jac/dkw217

Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; Van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA, 2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331

Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K, 2016, 'Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial', The Lancet HIV, 3, pp. e343 - e350, http://dx.doi.org/10.1016/S2352-3018(16)30010-8

Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R, 2016, 'Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study', Clinical Pharmacokinetics, 55, pp. 861 - 873, http://dx.doi.org/10.1007/s40262-015-0360-5

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S; Cooper D, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207

Revell A; Khabo P; Ledwaba L; Emery S; Wang D; Wood R; Morrow C; Tempelman H; Hamers RL; Reiss P; van Sighem A; Pozniak A; Montaner J; Lane HC; Larder B, 2016, 'Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa', SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 17, http://dx.doi.org/10.4102/sajhivmed.v17i1.450

Back to profile page